Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 7, 2011, Pages 395-404

  Thorsteinsdottir, Sigrun ^a   Gudjonsson, Thorkell ^a   Nielsen, Ole Haagen ^a   Vainer, Ben ^a   Seidelin, Jakob Benedict ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CROHN DISEASE; DNA ADDUCT; DNA DAMAGE; DYSPLASIA; GENE MUTATION; HUMAN; INFLAMMATION; INTESTINE BIOPSY; LIPID PEROXIDATION; MICROSATELLITE INSTABILITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRECANCER; PRIORITY JOURNAL; REVIEW; SENESCENCE; TELOMERE; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

CHROMOSOMAL INSTABILITY; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; HUMANS; MUTATION; REACTIVE OXYGEN SPECIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960091761     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.96     Document Type: Review

References (123)

1. Winther, K. V., Jess, T., Langholz, E., Munkholm, P. & Binder, V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 125, 1576-1582 (2003) (Pubitemid 37500420)
2. Baumgart, D. C. & Sandborn, W. J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369, 1641-1657 (2007) (Pubitemid 46722637)
3. Eaden, J. A., Abrams, K. R. & Mayberry, J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535 (2001) (Pubitemid 32234798)
4. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) [online], http://seer.cancer.gov/(2010)
5. Riddell, R. H., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 14, 931-968 (1983)
6. Itzkowitz, S. H. & Yio, X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G7-G17 (2004) (Pubitemid 38802113)
7. Rutter, M., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126, 451-459 (2004) (Pubitemid 38182302)
8. Abraham, C. & Cho, J. H. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066-2078 (2009)
9. Cario, E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm. Bowel Dis. 16, 1583-1597 (2010)
10. Ogier-Denis, E., Mkaddem, S. B. & Vandewalle, A. NOX enzymes and Toll-like receptor signaling. Semin. Immunopathol. 30, 291-300 (2008)
11. Roessner, A., Kuester, D., Malfertheiner, P. & Schneider-Stock, R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 204, 511-524 (2008)
12. Rosen, G. M., Pou, S., Ramos, C. L., Cohen, M. S. & Britigan, B. E. Free radicals and phagocytic cells. FASEB J. 9, 200-209 (1995)
13. Jackson, A. L. & Loeb, L. A. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat. Res. 477, 7-21 (2001) (Pubitemid 32480184)
14. Grisham, M. B. Oxidants and free radicals in inflammatory bowel disease. Lancet 344, 859-861 (1994) (Pubitemid 24290387)
15. Sawa, T. & Ohshima, H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 14, 91-100 (2006) (Pubitemid 43165874)
16. Caulfield, J. L., Wishnok, J. S. & Tannenbaum, S. R. Nitric oxide-induced deamination of cytosine and guanine in deoxynucleosides and oligonucleotides. J. Biol. Chem. 273, 12689-12695 (1998) (Pubitemid 28246819)
17. Sawa, T., Akaike, T. & Maeda, H. Tyrosine nitration by peroxynitrite formed from nitric oxide and superoxide generated by xanthine oxidase. J. Biol. Chem. 275, 32467-32474 (2000)
18. Kennedy, L. J., Moore, K. Jr, Caulfield, J. L., Tannenbaum, S. R. & Dedon, P. C. Quantitation of 8-oxoguanine and strand breaks produced by four oxidizing agents. Chem. Res. Toxicol. 10, 386-392 (1997) (Pubitemid 27176299)
19. Salgo, M. G., Bermdez, E., Squadrito, G. L. & Pryor, W. A. Peroxynitrite causes DNA damage and oxidation of thiols in rat thymocytes [corrected]. Arch. Biochem. Biophys. 322, 500-505 (1995)
20. Juedes, M. J. & Wogan, G. N. Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and in human cells. Mutat. Res. 349, 51-61 (1996) (Pubitemid 26026758)
21. Marnett, L. J. Oxy radicals, lipid peroxidation and DNA damage. Toxicology 181-182, 219-222 (2002) (Pubitemid 36015702)
22. Simmonds, N. J., et al. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 103, 186-196 (1992)
23. Keshavarzian, A., et al. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 103, 177-185 (1992)
24. Kruidenier, L., Kuiper, I., Lamers, C. B. & Verspaget, H. W. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J. Pathol. 201, 28-36 (2003) (Pubitemid 37121200)
25. Andresen, L., et al. Activation of nuclear factor B in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54, 503-509 (2005) (Pubitemid 40395502)
26. Seidelin, J. B. & Nielsen, O. H. Continuous cytokine exposure of colonic epithelial cells induces DNA damage. Eur. J. Gastroenterol. Hepatol. 17, 363-369 (2005) (Pubitemid 40411225)
27. Kimura, H., et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 42, 180-187 (1998) (Pubitemid 28212172)
28. Hussain, S. P., Hofseth, L. J. & Harris, C. C. Radical causes of cancer. Nat. Rev. Cancer 3, 276-285 (2003) (Pubitemid 37328863)
29. Sánchez-Alcázar, J. A., et al. Tumor necrosis factor-β increases the steady-state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. J. Biol. Chem. 275, 13353-13361 (2000) (Pubitemid 30257394)
30. Schulze-Osthoff, K., et al. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J. Biol. Chem. 267, 5317-5323 (1992)
31. Yan, B., et al. Tumor necrosis factor-β is a potent endogenous mutagen that promotes cellular transformation. Cancer Res. 66, 11565-11570 (2006) (Pubitemid 46094163)
32. Holmes, E. W., Yong, S. L., Eiznhamer, D. & Keshavarzian, A. Glutathione content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis. Dig. Dis. Sci. 43, 1088-1095 (1998) (Pubitemid 28211471)
33. Koutroubakis, I. E., et al. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig. Dis. Sci. 49, 1433-1437 (2004) (Pubitemid 39273618)
34. Wu, W. S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 25, 695-705 (2006)
35. Svineng, G., Ravuri, C., Rikardsen, O., Huseby, N. E. & Winberg, J. O. The role of reactive oxygen species in integrin and matrix metalloproteinase expression and function. Connect. Tissue Res. 49, 197-202 (2008)
36. Itzkowitz, S. H., Present, D. H. & Crohns and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm. Bowel Dis. 11, 314-321 (2005) (Pubitemid 40439686)
37. Chambers, W. M., Warren, B. F., Jewell, D. P. & Mortensen, N. J. Cancer surveillance in ulcerative colitis. Br. J. Surg. 92, 928-936 (2005) (Pubitemid 41160781)
38. Fujii, S., Katsumata, D. & Fujimori, T. Limits of diagnosis and molecular markers for early detection of ulcerative colitis-associated colorectal neoplasia. Digestion 77 (Suppl. 1), 2-12 (2008) (Pubitemid 351598542)
39. Melville, D. M., et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum. Pathol. 20, 1008-1014 (1989) (Pubitemid 19267907)
40. Collins, P. D., Mpofu, C., Watson, A. J. & Rhodes, J. M. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD000279. doi:10.1002/14651858.CD000279.pub3 (2006)
41. Brentnall, T. A., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107, 369-378 (1994) (Pubitemid 24233310)
42. Leedham, S. J., et al. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 136, 542-550 (2009)
43. Powell, S. M., et al. APC mutations occur early during colorectal tumorigenesis. Nature 359, 235-237 (1992)
44. Holzmann, K., et al. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int. J. Cancer 76, 1-6 (1998) (Pubitemid 28164560)
45. Hussain, S. P., et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 60, 3333-3337 (2000) (Pubitemid 30482141)
46. Lashner, B. A., Shapiro, B. D., Husain, A. & Goldblum, J. R. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am. J. Gastroenterol. 94, 456-462 (1999) (Pubitemid 29084669)
47. Ambs, S., et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl Cancer Inst. 91, 86-88 (1999) (Pubitemid 29042448)
48. Fujii, S., Fujimori, T. & Chiba, T. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia. J. Exp. Clin. Cancer Res. 22, 107-115 (2003) (Pubitemid 36396665)
49. Finlay, C. A., et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell Biol. 8, 531-539 (1988)
50. Vousden, K. H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 1602, 47-59 (2002) (Pubitemid 34311899)
51. Brooks, C. L. & Gu, W. Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle 3, 895-899 (2004) (Pubitemid 40179468)
52. Seril, D. N., Liao, J., Yang, G. Y. & Yang, C. S. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24, 353-362 (2003) (Pubitemid 36432628)
53. Willenbucher, R. F., Zelman, S. J., Ferrell, L. D., Moore, D. H. 2nd & Waldman, F. M. Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 113, 791-801 (1997) (Pubitemid 27381138)
54. Aust, D. E., et al. Chromosomal alterations in ulcerative colitis-related and sporadic colorectal cancers by comparative genomic hybridization. Hum. Pathol. 31, 109-114 (2000) (Pubitemid 30054395)
55. Willenbucher, R. F., et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am. J. Pathol. 154, 1825-1830 (1999) (Pubitemid 29262864)
56. Chen, R., et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am. J. Pathol. 162, 665-672 (2003) (Pubitemid 36267873)
57. Rabinovitch, P. S., et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res. 59, 5148-5153 (1999) (Pubitemid 29503975)
58. Bronner, M. P., et al. Genomic biomarkers to improve ulcerative colitis neoplasia surveillance. Am. J. Pathol. 173, 1853-1860 (2008)
59. Jackson, S. P. Sensing and repairing DNA double-strand breaks. Carcinogenesis 23, 687-696 (2002) (Pubitemid 34567505)
60. Karanjawala, Z. E., Murphy, N., Hinton, D. R., Hsieh, C. L. & Lieber, M. R. Oxygen metabolism causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA double-strand break repair mutants. Curr. Biol. 12, 397-402 (2002) (Pubitemid 34209287)
61. Dickey, J. S., et al. H2AX: functional roles and potential applications. Chromosoma 118, 683-692 (2009)
62. Fernandez-Capetillo, O., Lee, A., Nussenzweig, M. & Nussenzweig, A. H2AX: the histone guardian of the genome. DNA Repair (Amst.) 3, 959-967 (2004) (Pubitemid 38997938)
63. Vilenchik, M. M. & Knudson, A. G. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc. Natl Acad. Sci. USA 100, 12871-12876 (2003) (Pubitemid 37339992)
64. Cahill, D., Connor, B. & Carney, J. P. Mechanisms of eukaryotic DNA double strand break repair. Front. Biosci. 11, 1958-1976 (2006) (Pubitemid 43253408)
65. Rogakou, E. P., Boon, C., Redon, C. & Bonner, W. M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146, 905-916 (1999)
66. Nuciforo, P. G., Luise, C., Capra, M., Pelosi, G. & dAdda di Fagagna, F. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 28, 2082-2088 (2007) (Pubitemid 47543366)
67. Blanco, D., et al. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 9, 840-852 (2007) (Pubitemid 47623424)
68. Tanaka, T., et al. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 71, 648-661 (2007) (Pubitemid 47351228)
69. Risques, R. A., et al. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res. 71, 1669-1679 (2011)
70. Risques, R. A., et al. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 135, 410-418 (2008)
71. OSullivan, J. N., et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet. 32, 280-284 (2002)
72. von Zglinicki, T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 27, 339-344 (2002) (Pubitemid 34756516)
73. dAdda di Fagagna, F., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 (2003).
74. Ben-Porath, I. & Weinberg, R. A. The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 37, 961-976 (2005) (Pubitemid 40311739)
75. Collado, M. & Serrano, M. The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer 6, 472-476 (2006)
76. Coppé, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99-118 (2010)
77. Wang, D., Kreutzer, D. A. & Essigmann, J. M. Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat. Res. 400, 99-115 (1998) (Pubitemid 28440215)
78. Valavanidis, A., Vlachogianni, T. & Fiotakis, C. 8-hydroxy-2′- deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 27, 120-139 (2009)
79. Kamiya, H., et al. 8-hydroxyguanine (7,8-dihydro-8-oxoguanine) in hot spots of the c-Ha-ras gene: effects of sequence contexts on mutation spectra. Carcinogenesis 16, 883-889 (1995)
80. Klein, J. C., et al. Repair and replication of plasmids with site-specific 8-oxodG and 8-AAFdG residues in normal and repair-deficient human cells. Nucleic Acids Res. 20, 4437-4443 (1992)
81. DInc, R., et al. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm. Bowel Dis. 10, 23-27 (2004)
82. Gushima, M., et al. Altered expression of MUTYH and an increase in 8-hydroxydeoxyguanosine are early events in ulcerative colitis-associated carcinogenesis. J. Pathol. 219, 77-86 (2009)
83. European Standards Committee on Oxidative DNA Damage (ESCODD). Measurement of DNA oxidation in human cells by chromatographic and enzymic methods. Free Radic. Biol. Med. 34, 1089-1099 (2003)
84. ESCODD (European Standards Committee on Oxidative DNA Damage). Comparative analysis of baseline 8-oxo-7, 8-dihydroguanine in mammalian cell DNA, by different methods in different laboratories: an approach to consensus. Carcinogenesis 23, 2129-2133 (2002)
85. Rodriguez, H., Jurado, J., Laval, J. & Dizdaroglu, M. Comparison of the levels of 8-hydroxyguanine in DNA as measured by gas chromatography mass spectrometry following hydrolysis of DNA by Escherichia coli Fpg protein or formic acid. Nucleic Acids Res. 28, E75 (2000)
86. Löfberg, R., Broström, O., Karlén, P., Ost, A. & Tribukait, B. DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 102, 1149-1154 (1992)
87. Rubin, C. E., et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103, 1611-1620 (1992)
88. Rutegård, J., Ahsgren, L., Stenling, R. & Roos, G. DNA content and mucosal dysplasia in ulcerative colitis. Flow cytometric analysis in patients with dysplastic or indefinite morphologic changes in the colorectal mucosa. Dis. Colon Rectum 32, 1055-1059 (1989) (Pubitemid 20020195)
89. Befrits, R., Hammarberg, C., Rubio, C., Jaramillo, E. & Tribukait, B. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis. Colon Rectum 37, 313-319 (1994)
90. Risques, R. A., Rabinovitch, P. S. & Brentnall, T. A. Cancer surveillance in inflammatory bowel disease: new molecular approaches. Curr. Opin. Gastroenterol. 22, 382-390 (2006) (Pubitemid 44090193)
91. Stenling, R., Jonsson, B. O., Palmqvist, R. & Rutegård, J. N. DNA aneuploidy in ulcerative colitis and in colorectal carcinoma-a comparative study. Anal. Cell Pathol. 18, 69-72 (1999) (Pubitemid 29356226)
92. Thibodeau, S. N., Bren, G. & Schaid, D. Microsatellite instability in cancer of the proximal colon. Science 260, 816-819 (1993) (Pubitemid 23167612)
93. Rhyu, M. G., Park, W. S. & Meltzer, S. J. Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene 9, 29-32 (1994) (Pubitemid 24020930)
94. Fleisher, A. S., et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 60, 4864-4868 (2000)
95. Brentnall, T. A., et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 56, 1237-1240 (1996) (Pubitemid 26080961)
96. Fujiwara, I., Yashiro, M., Kubo, N., Maeda, K. & Hirakawa, K. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis. Colon Rectum 51, 1387-1394 (2008)
97. Løvig, T., Andersen, S. N., Clausen, O. P. & Rognum, T. O. Microsatellite instability in long-standing ulcerative colitis. Scand. J. Gastroenterol. 42, 586-591 (2007) (Pubitemid 46633813)
98. Tahara, T., et al. Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 20, 710-715 (2005) (Pubitemid 40733364)
99. Boland, C. R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248-5257 (1998) (Pubitemid 28521189)
100. Ritz-Timme, S. & Collins, M. J. Racemization of aspartic acid in human proteins. Ageing Res. Rev. 1, 43-59 (2002) (Pubitemid 38340351)
101. Went, P. T., Sauter, G., Oberholzer, M. & Bubendorf, L. Abundant expression of AMACR in many distinct tumour types. Pathology 38, 426-432 (2006) (Pubitemid 44478869)
102. Tosoian, J. & Loeb, S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal 10, 1919-1931 (2010)
103. Dorer, R. & Odze, R. D. AMACR immunostaining is useful in detecting dysplastic epithelium in Barretts esophagus, ulcerative colitis, and Crohns disease. Am. J. Surg. Pathol. 30, 871-877 (2006) (Pubitemid 44264978)
104. Gerdes, J., et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol. 138, 867-873 (1991)
105. Andersen, S. N., Rognum, T. O., Bakka, A. & Clausen, O. P. Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis. Mol. Pathol. 51, 327-332 (1998) (Pubitemid 29003269)
106. Wong, N. A., Mayer, N. J., MacKell, S., Gilmour, H. M. & Harrison, D. J. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology 37, 108-114 (2000) (Pubitemid 30608507)
107. Noffsinger, A. E., Miller, M. A., Cusi, M. V. & Fenoglio-Preiser, C. M. The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis. Cancer 78, 2307-2312 (1996) (Pubitemid 26392828)
108. Bartsch, H. & Nair, J. Accumulation of lipid peroxidation-derived DNA lesions: potential lead markers for chemoprevention of inflammation-driven malignancies. Mutat. Res. 591, 34-44 (2005) (Pubitemid 41654838)
109. Nair, J., et al. Increased etheno-DNA adducts in affected tissues of patients suffering from Crohns disease, ulcerative colitis, and chronic pancreatitis. Antioxid. Redox Signal. 8, 1003-1010 (2006) (Pubitemid 44036517)
110. van Staa, T. P., Card, T., Logan, R. F. & Leufkens, H. G. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54, 1573-1578 (2005) (Pubitemid 41531774)
111. Velayos, F. S., Terdiman, J. P. & Walsh, J. M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol. 100, 1345-1353 (2005) (Pubitemid 40904360)
112. Clapper, M. L., et al. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 14, 1341-1347 (2008)
113. Ahnfelt-Rønne, I., et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 98, 1162-1169 (1990) (Pubitemid 20143098)
114. Nielsen, O. H. In vitro studies on the significance of arachidonate metabolism and other oxidative processes in the inflammatory response of human neutrophils and macrophages. With special reference to chronic inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 150, 1-21 (1988)
115. Nielsen, O. H. & Munck, L. K. Drug insight: aminosalicylates for the treatment of IBD. Nat. Clin. Pract Gastroenterol. Hepatol. 4, 160-170 (2007) (Pubitemid 46416252)
116. Yppolito, R., et al. On the antioxidant properties of therapeutic drugs: quenching of singlet molecular oxygen by aminosalicylic acids. Redox Rep. 7, 229-233 (2002)
117. Simmonds, N. J., Millar, A. D., Blake, D. R. & Rampton, D. S. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment. Pharmacol. Ther. 13, 363-372 (1999) (Pubitemid 29142046)
118. Luciani, M. G., Campregher, C., Fortune, J. M., Kunkel, T. A. & Gasche, C. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 132, 221-235 (2007) (Pubitemid 46108738)
119. Stolfi, C., et al. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem. Pharmacol. 75, 668-676 (2008)
120. Koelink, P. J., et al. 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes. Inflamm. Bowel Dis. 16, 379-389 (2010)
121. Speckmann, B., et al. Proinflammatory cytokines down-regulate intestinal selenoprotein P biosynthesis via NOS2 induction. Free Radic. Biol. Med. 49, 777-785 (2010)
122. Linehan, J. D., Kolios, G., Valatas, V., Robertson, D. A. & Westwick, J. Immunomodulatory cytokines suppress epithelial nitric oxide production in inflammatory bowel disease by acting on mononuclear cells. Free Radic. Biol. Med. 39, 1560-1569 (2005) (Pubitemid 41642587)
123. Potoka, D. A., et al. Inhibition of NF-κB by IB prevents cytokine-induced NO production and promotes enterocyte apoptosis in vitro. Shock 14, 366-373 (2000)